Similarly, FRDA patients’ iPSC-based models have facilitated the identification of promising therapeutic strategies, such as GLP-1R agonists, which enhance frataxin expression and improve mitochondrial function [84]. The gene discussed is FXN; the disease is Friedreich ataxia.